American Society of Hematology

Figure 1.

$Figure 1. Hematopoietic progenitor mutation burden. (A) Experimental schema. CD34+ CD38− lineage− cells from blood (Nm1, Nm4, and cord blood) or bone marrow were sorted 1 cell per well and expanded on stromal support for 2 to 4 weeks. Exome sequencing was performed on 4 hematopoietic progenitor clones isolated from 6 healthy donors, 3 cord blood, 11 SCN, or 2 SDS patients. Somatic mutations were identified by comparison with exome sequence data from matched unfractionated blood or bone marrow leukocytes. (B) The number of somatic SNVs per exome for each clone. (C) The average number of somatic SNVs per hematopoietic progenitor exome vs age at sample collection. (D) The average number of somatic SNVs per exome. The mean ± standard error of the mean is shown. BM, bone marrow; HPC, hematopoietic progenitor cell; ND, not determined; NM, healthy volunteers.$

Hematopoietic progenitor mutation burden. (A) Experimental schema. CD34⁺ CD38⁻ lineage⁻ cells from blood (Nm1, Nm4, and cord blood) or bone marrow were sorted 1 cell per well and expanded on stromal support for 2 to 4 weeks. Exome sequencing was performed on 4 hematopoietic progenitor clones isolated from 6 healthy donors, 3 cord blood, 11 SCN, or 2 SDS patients. Somatic mutations were identified by comparison with exome sequence data from matched unfractionated blood or bone marrow leukocytes. (B) The number of somatic SNVs per exome for each clone. (C) The average number of somatic SNVs per hematopoietic progenitor exome vs age at sample collection. (D) The average number of somatic SNVs per exome. The mean ± standard error of the mean is shown. BM, bone marrow; HPC, hematopoietic progenitor cell; ND, not determined; NM, healthy volunteers.

This Feature Is Available To Subscribers Only